5results about How to "The crystallization process is easy to control" patented technology

This invention belongs to the technical field of medicinal chemistry and provides a milrinone-tartaric acid cocrystal. Using Cu-Kα radiation, its X-ray diffraction pattern (expressed as 2θ) exhibits characteristic peaks at at least 10.0±0.2°, 13.2±0.2°, 20.4±0.2°, 24.7±0.2°, 26.2±0.2°, 26.7±0.2°, and 34.3±0.2°. The cocrystal of this invention has high solubility and good stability. Using this cocrystal to prepare formulations avoids the use of large amounts of excipients and auxiliaries in existing technologies, reducing both production costs and clinical safety risks. The preparation method of the milrinone-tartaric acid cocrystal provided by this invention is simple to operate, the crystallization process is easy to control, and it has good reproducibility.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a new mirinol crystal form, and particularly to a mirinol-adipic acid co-crystal and a preparation method and application thereof. The co-crystal has an X-ray diffraction spectrum expressed by 2theta using Cu-Kalpha radiation, and has characteristic peaks at least at 9.0+ / -0.2°, 15.7+ / -0.2°, 18.0+ / -0.2°, 24.0+ / -0.2°, 31.4+ / -0.2°, 31.6+ / -0.2°. The preparation method of the mirinol-adipic acid co-crystal is simple in operation, easy to control in crystallization process, and good in reproducibility.

The present application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a crystal form of lamivudine salt of m-hydroxybenzoic acid and a preparation method thereof. The crystal form has an X-ray diffraction spectrum expressed by 2theta using Cu-Kalpha radiation, and has characteristic peaks at least at 9.26+ / -0.2, 12.56+ / -0.2, 13.05+ / -0.2, 14.59+ / -0.2, 17.45+ / -0.2, 20.30+ / -0.2, 21.76+ / -0.2, 23.37+ / -0.2, 25.05+ / -0.2 and 27.58+ / -0.2; the crystal form is composed of a molecule of lamivudine, a molecule of m-hydroxybenzoic acid and a molecule of n-butanol as a basic unit; meanwhile, the crystal form has good solubility, provides ideal raw material for preparing parenteral dosage forms which are convenient to administer and have rapid effect, and thus better meets the requirements of clinical application.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a milrinone-citric acid dihydrate co-crystal. The application provides a new milrinone-citric acid dihydrate co-crystal and a preparation method thereof. The co-crystal has excellent properties, can significantly enhance the solubility and stability of milrinone, is helpful to improve the oral bioavailability, improve the clinical curative effect, has strong drug-making value, the preparation method is simple in operation and easy to control, and is suitable for industrial amplification.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a new crystal form of cabozantinib, a preparation method and application thereof. The new crystal form provided by the application is a cabozantinib-amino sulfonic acid-methanol co-crystal, wherein one molecule of cabozantinib, one molecule of amino sulfonic acid and one molecule of methanol form a basic unit of the crystal form, and great improvement is achieved in stability, solubility and the like, the preparation method is simple in operation, good in reproducibility and suitable for industrialized production.